ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Arcellx Inc

Arcellx Inc (ACLX)

62.23
-3.28
(-5.01%)
At close: July 18 4:00PM
62.24
0.01
( 0.02% )
After Hours: 4:01PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
62.24
Bid
61.00
Ask
63.45
Volume
408,477
61.80 Day's Range 66.52
30.88 52 Week Range 75.10
Market Cap
Previous Close
65.51
Open
65.03
Last Trade
3
@
62.24
Last Trade Time
16:03:20
Financial Volume
$ 25,819,613
VWAP
63.2095
Average Volume (3m)
484,199
Shares Outstanding
53,502,572
Dividend Yield
-
PE Ratio
-46.93
Earnings Per Share (EPS)
-1.32
Revenue
110.32M
Net Profit
-70.69M

About Arcellx Inc

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arcellx Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ACLX. The last closing price for Arcellx was $65.51. Over the last year, Arcellx shares have traded in a share price range of $ 30.88 to $ 75.10.

Arcellx currently has 53,502,572 shares outstanding. The market capitalization of Arcellx is $3.50 billion. Arcellx has a price to earnings ratio (PE ratio) of -46.93.

ACLX Latest News

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.566.0668029993258.6867.3758.3362116963.54186656CS
48.4715.752278222153.7767.3752.7252060057.6183137CS
1211.1721.871940473951.0767.3747.8848419954.25810702CS
267.0412.753623188455.275.147.8846893259.19851246CS
5227.9981.722627737234.2575.130.8852687250.31974126CS
15643.24227.5789473681975.16.03548134037.48649934CS
26043.24227.5789473681975.16.03548134037.48649934CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DRUGBright Minds Biosciences Inc
$ 1.43
(31.19%)
121.8k
NVNINVNI Group Ltd
$ 1.40
(9.38%)
593
IPDNProfessional Diversity Network Inc
$ 0.5741
(9.35%)
111
PHIOPhio Pharmaceuticals Corporation
$ 4.7499
(8.72%)
200
MYSZMy Size Inc
$ 3.67
(7.81%)
7.7k
CRSRCorsair Gaming Inc
$ 8.88
(-8.74%)
28.82k
PLUGPlug Power Inc
$ 2.74
(-6.00%)
947.78k
GVHGlobavend Holdings Ltd
$ 0.6109
(-6.00%)
1.35k
SCHLScholastic Corporation
$ 34.50
(-5.61%)
2.59k
SILOSilo Pharma Inc
$ 3.2702
(-5.18%)
93.91k
NVDANVIDIA Corporation
$ 121.78
(0.39%)
1.73M
PLUGPlug Power Inc
$ 2.74
(-6.00%)
947.78k
TLTiShares 20 plus Year Treasury Bond
$ 93.46
(-0.04%)
757.92k
SQQQProShares UltraPro Short QQQ
$ 8.24
(0.06%)
610.63k
ONCOOnconetix Inc
$ 0.21
(-1.22%)
586.65k

ACLX Discussion

View Posts
Monksdream Monksdream 3 months ago
ACLX over $30
👍️0
Monksdream Monksdream 6 months ago
ACLX new 52 week high
👍️0
Monksdream Monksdream 6 months ago
ACLX new 52 week high
👍️0
Monksdream Monksdream 6 months ago
ACLX new 52 week high
👍️0
bandit007 bandit007 2 years ago
Going beast mode into next week.
👍️0
TheyWantYourShares TheyWantYourShares 2 years ago
Nice correction coming here. New IPO at 16… company is flush with capital/cash. Moves coming and getting in now will pay off big IMHO.


Got in on the drop @average: 13.12 … 2 and 3 days ago.


$ACLX


GLTA!!



-TWYS
👍️0
crudeoil24 crudeoil24 2 years ago
Net loss of $44M > no revenues! ( over 9 month period)

ACLX
👍️0
crudeoil24 crudeoil24 2 years ago
Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share. With 33.54 million shares expected to be outstanding after the IPO, the expected pricing could value the company at up to $570.24 million. The stock is expected to list on the Nasdaq under the ticker symbol "ACLX." BofA Securities, SVB Leerink, Barclays and William Blair are the lead underwriters. The company recorded a net loss of $44.30 million on no revenue during the nine months ended Sept. 30, after a loss of $23.00 million on no revenue in the same period a year ago. Arcellx is looking to go public at a time of relative investor disdain for IPOs and biotechs, as the Renaissance IPO ETF IPO, -3.27% has plunged 37.2% over the past three months and the iShares Biotechnology ETF IBB, -1.39% has tumbled 19.8%, while the S&P 500 SPX, +0.31% has slipped 3.8%.
👍️0